Kidney function endpoints in kidney transplant trials: A struggle for power

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 707-713

  Ibrahim, A ^a   Garg, A X ^b   Knoll, G A ^c,d,e   Akbari, A ^c,d,e   White, C A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d Kidney Research Centre   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Glomerular filtration rate; graft function; kidney transplantation; randomized controlled trials; systematic review

Indexed keywords

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; POWER ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL ANALYSIS; SURGICAL PATIENT; SURGICAL TECHNIQUE;

GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MODELS, STATISTICAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 84874424971     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12050     Document Type: Article

References (34)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242.
3. Russell JD, Beecroft ML, Ludwin D, Churchill DN,. The quality of life in renal transplantation-A prospective study. Transplantation 1992; 54: 656-660.
4. 2008 USRDS Annual Data Report-Atlas of End-Stage Renal Disease. 2008.
5. He X, Moore J, Shabir S, et al. Comparison of the predictive performance of eGFR formulae for mortality and graft failure in renal transplant recipients. Transplantation 2009; 87: 384-392.
6. Mariat C, Alamartine E, Barthelemy JC, et al. Assessing renal graft function in clinical trials: Can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004; 65: 289-297.
7. Kaplan B, Schold J, Meier-Kriesche HU,. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003; 3: 1560-1565.
8. Hariharan S, McBride MA, Cohen EP,. Evolution of endpoints for renal transplant outcome. Am J Transplant 2003; 3: 933-941.
9. Vincenti F,. Beyond belatacept: Praise and progress for the FDA. Am J Transplant 2012; 12: 513-514.
10. Schold JD, Kaplan B,. The elephant in the room: Failings of current clinical endpoints in kidney transplantation. Am J Transplant 2010; 10: 1163-1166.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
12. Lachenbruch PA, Rosenberg AS, Bonvini E, Cavaille-Coll MW, Colvin RB,. Biomarkers and surrogate endpoints in renal transplantation: Present status and considerations for clinical trial design. Am J Transplant 2004; 4: 451-457.
13. Hernandez D, Rufino M, Gonzalez-Posada JM, Torres A, Pascual J,. Surrogate end points for graft failure and mortality in kidney transplantation. Transplant Rev 2007; 21: 97-106.
14. White CA, Siegal D, Akbari A, Knoll GA,. Use of kidney function end points in kidney transplant trials: A systematic review. Am J Kidney Dis 2010; 56: 1140-1157.
15. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J,. Summary of the US FDA approval of belatacept. Am J Transplant 2012; 12: 554-562.
16. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307-316.
17. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study. Am J Transplant 2010; 10: 547-557.
18. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
19. Fellstrom B, Holdaas H, Jardine AG, et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66: 1549-1555.
20. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
21. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62-68.
22. Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78: 1204-1211.
23. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study. Am J Transplant 2010; 10: 535-546.
24. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
25. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785.
26. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.
27. Kasiske BL, Israni AK, Snyder JJ, Skeans MA,.; Patient Outcomes in Renal Transplantation (PORT) Investigators. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011; 57: 466-475.
28. Foucher Y, Daguin P, Akl A, et al. A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int 2010; 78: 1288-1294.
29. Stevens LA, Greene T, Levey AS,. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1: 874-884.
30. Tape TG,. Interpreating Diagnostic Tests. Available at: http://gim.unmc.edu/dxtests/Default.htm. Accessed December 5, 2012.
31. White CA, Huang D, Akbari A, Garland J, Knoll GA,. Performance of creatinine-based estimates of GFR in kidney transplant recipients: A systematic review. Am J Kidney Dis 2008; 51: 1005-1015.
32. Levin A, Beaulieu MC,. Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. J Am Soc Nephrol 2011; 22: 992-993.
33. Mariat C, Maillard N, Phayphet M, et al. Estimated glomerular filtration rate as an end point in kidney transplant trial: Where do we stand? Nephrol Dial Transplant 2008; 23: 33-38.
34. FHN Trial Group;, Chertow GM, Levin NW, Beck GJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300.